Data as of Dec 17
| +1.94 / +1.93%|
The 24 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 126.50, with a high estimate of 170.00 and a low estimate of 82.00. The median estimate represents a +23.54% increase from the last price of 102.40.
The current consensus among 27 polled investment analysts is to Buy stock in Gilead Sciences. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.